Novartis’s recent acquisition streak is pivoting the company toward new treatments that bear little resemblance to traditional drugs.
The Swiss company has spent nearly $15 billion in the past year to build its presence in cutting-edge areas of medical research, including gene therapy, or treatments that introduce new DNA into the body, and radiopharmaceuticals, which are drugs that carry radioactive particles to tumours for close-range radiotherapy. 543 more words